Inotuzumab Ozogamicin, a Nonchemotherapy Option for Relapsed Acute Lymphoblastic Leukemia

H&O What percentage of patients with ALL will develop relapsed disease, and what is their prognosis? HK Among adult and elderly patients with acute lymphoblastic […]

Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia

Abstract: Patients with relapsed or refractory acute lymphoblastic leukemia (R/R ALL) have dismal outcomes, with survival of less than 6 months, and treatment options in […]